Nuvation Bio appoints Robert Mashal, M.D. to board as Class II director

Nuvation Bio Inc.

Dr. Mashal appointed to fill vacant board seat effective Jan. 8, 2024; term expires at 2026 annual meeting.
He is a former global head of strategy for immunology/oncology at Sanofi and a board-certified medical oncologist.
Received initial option grant of $770,000 in Class A common stock vesting monthly over three years.
Also eligible for annual cash retainer of $40,000; no committee assignment as of filing date.
Board determined Dr. Mashal qualifies as independent under NYSE listing rules.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert Mashal

Director

NUVB · Nuvation Bio Inc.

Effective: 2024-01-08
Filed: January 8, 2024, 6:59 PM ET

On January 8, 2024 the Board of Directors (the “ Board ”) of Nuvation Bio Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Mashal, M.D. to fill a vacant Board seat and to serve as a Class II director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Mashal was appointed as Director at Nuvation Bio Inc..

Action: appointed
Role: Director

Exact text from the filing

On January 8, 2024 the Board of Directors (the “ Board ”) of Nuvation Bio Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Robert Mashal, M.D. to fill a vacant Board seat and to serve as a Class II director, with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.

View on SEC.gov

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-004426

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.